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Populations and their health are dy-
namic. Societal, environmental, and eco-
nomic changes lead to changes in rates of
birth, death, and disease, often described
as transitions in mortality, demography,
and epidemiology. The notion of epide-
miologic transition provides an insight into
the relationship between levels of overall
mortality and the distribution of its causes
[1–3], in which the greatest changes arise
from the survival of children and young
women. Recent falls in global child
mortality are good news [4], but will lead
to increases in the relative burdens of
morbidity and disability in children who
would previously have died, and of
congenital malformations and inherited
disorders. The work of Fre´de´ric Piel and
colleagues on sickle cell anaemia (SCA),
published in this week’s PLOS Medicine [5],
speaks strongly to this point: SCA is an
inherited disease whose global importance
will increase in terms of absolute numbers
and relative population burden. SCA
occurs when individuals are homozygous
for sickle haemoglobin (HbS) in place of
normal adult haemoglobin, and is the
most common form of sickle cell disorder
(SCD) [6]. Piel and colleagues have
collated HbS allele frequency surveys
and used them in models to generate a
global distribution map and estimate the
numbers of infants born heterozygotic and
homozygotic for HbS. Using population
and mortality projections, they predict an
increase in the numbers of newborns with
SCA to over 400,000 in 2050. They also
estimate the potential mortality effects of
four care-provision scenarios, with a best-
case scenario that between 7.5 and 15.5
million newborn lives could be saved, most
of them in Africa.
Modelled estimates are a growth area in
global health. Whilst useful at supra-
national and national levels, their emer-
gence highlights the lack of reliable data
on populations, disease, and mortality
across most of the world: precisely the
sort of information that policy makers and
health planners need. The utility of
estimates for planning screening pro-
grammes, infrastructural and human re-
source requirements, and clinical care
protocols at sub-national levels is likely to
be limited where the generalisability of
assumptions is challenged by diversity at
the local level. Even at a global level,
estimates can cause confusion. Research
teams using different models may, for
example, come to different conclusions
[7]. Piel et al. have combined available
data, statistical methods, and assumptions
to predict current burdens and future
trends. Their uncertainties are described
clearly, and a preoccupation with meth-
odological critiques can easily distract us
from the public health concerns that
estimates raise.
The epidemiologic transition has been
reframed as a health transition that
involves sociocultural, behavioural, and
health service factors [8], and policy and
health services must respond to changing
disease burdens. Unfortunately, the notion
of transitions is general. Parallel transitions
are happening in different groups within
one nation, the best example being
differences between socioeconomic
groups. Rates of transition vary with local
environment, and counter-transition is
even possible [9]. Policy makers must set
priorities in an environment of multiple
burdens, unfinished agendas, competing
discourses, and the voices of interest
groups [10], a process that has been
described as a chaos of purposes and
accidents [11]. In an environment of
Realpolitik, the generation of estimates of
burden is important for advocacy. Char-
acteristically, investigators working in an
important public health field that has not
received global attention lay down the
strategic epidemiology [7,12], as Piel and
colleagues are doing, demonstrating that
lack of progress will hinder efforts to attain
targets such as those of the Millennium
Development Goals.
Quantifying the problem is important,
but not sufficient. In a consideration of
issue attention for newborn health, Jeremy
Shiffman considered four elements: the
power of the actors involved, new ideas
that can be brought to the table, the
characteristics of the issue in terms of
attractiveness and tractability, and politi-
cal context [13]. The kind of strategic
epidemiology that the SCA figures exem-
plify needs to be linked with granular
understanding of local epidemiology and
service provision [7]. SCA poses a partic-
ular challenge in terms of tractability.
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an emerging cure, is currently too costly a
technology for the countries on which the
burden predominantly falls, as is hydroxy-
urea therapy for children at high risk of
illness. Survival, health, and well-being
can all be improved substantially, but rely
on health care systems with a certain level
of functionality. Piel and colleagues sug-
gest that the priority is to identify births of
infants with SCA, but that such births
could be avoided through genetic coun-
selling and prenatal diagnosis. Termina-
tion of pregnancy is one of several options,
which include preconception genetic
screening and strategic reproductive choic-
es, education for carrier parents, and
holistic management from infancy. Quite
apart from the logistic and financial
challenges, these approaches raise substan-
tial ethical questions summarised in recent
work from Ghana [14].
Several interventions would be enor-
mously helpful. Routine newborn screen-
ing remains costly—but is likely to become
less so—and may miss infants born at
home. Penicillin prophylaxis and pneumo-
coccal immunisation are possible in most
health care systems. The most beneficial
approach involves comprehensive care
[15]: family education, routine immunisa-
tion, malaria prevention, nutrition and
hydration, prophylactic antibiotics, folic
acid supplements, transfusion when re-
quired, support groups for children and
their families, protocols for the manage-
ment of acute events by health workers
and—most importantly—regular follow-
up. Human resources for health need to
be well trained, and the medicines re-
quired need to be affordable and available,
including the pain relief required by many
people with SCD [16].
Steps towards a systematic approach are
being taken [17]. A 2006 World Health
Assembly resolution on SCA recommends
increased awareness in the international
community and emphasises collaboration
between countries, including technical
support, development of practice models,
and coordination [18]. The World Health
Organization has published a strategy for
the African Region, with targets that
include development and implementation
of national control programmes in mem-
ber states with high SCD prevalence,
adoption of comprehensive health care
management, and establishment of sur-
veillance systems [19]. The estimates from
Piel and colleagues underscore the need
for both collaborative responses and better
data for planning and monitoring.
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